Finasteride

Personalized Skincare Brand Curology Launches Into Hair Care Category With Hair Formula Rx

Retrieved on: 
Thursday, February 1, 2024
Nursing, SAN, Male, Life, DOS, Science, Fear, Hair loss, Patient, Spironolactone, Dermatology, MD, Skin, NPS, Female, PAS, Finasteride, Minoxidil, Scalp, Cosmetics

SAN FRANCISCO, Feb. 1, 2024 /PRNewswire/ -- Dermatologist-powered personalized skincare brand Curology announced today their launch into the hair care category with its latest innovation, Hair FormulaRx. This personalized prescription hair growth treatment contains clinically proven ingredients that help to regrow hair in as little as three months.*

Key Points: 
  • SAN FRANCISCO, Feb. 1, 2024 /PRNewswire/ -- Dermatologist-powered personalized skincare brand Curology announced today their launch into the hair care category with its latest innovation, Hair FormulaRx.
  • This personalized prescription hair growth treatment contains clinically proven ingredients that help to regrow hair in as little as three months.
  • If topical minoxidil is included in one's Hair FormulaRx, Curology offers higher strengths of minoxidil than what's available over-the-counter.
  • It's a leave-on topical hair solution that addresses multiple root causes of hair thinning for visibly thicker, stronger hair.

AUA Releases Amendment to the Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Guideline

Retrieved on: 
Thursday, September 14, 2023
PAE, Male, Prostatic artery embolization, Prevalence, Guideline, E pluribus unum, Epithelium, AUA, BPH, LUTS, Urethra, Ageing, American Urological Association, Prostate, Literature, MD, Patient, Finasteride, Water, Memorial Sloan Kettering Cancer Center, Diagnosis, Benign prostatic hyperplasia, System, ULR, Update, Medical imaging, Dietary supplement

BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the management of lower urinary tract symptoms attributed to benign prostatic hyperplasia.

Key Points: 
  • BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the management of lower urinary tract symptoms attributed to benign prostatic hyperplasia.
  • Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the production of smooth muscle and epithelial cells within the prostatic transition zone.
  • The prevalence and the severity of lower urinary tract symptoms (LUTS) in the aging male can be progressive and is an important diagnosis in the healthcare of patients and the welfare of society.
  • Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline amendment 2023.

$545+ Mn Finasteride Market - Global Opportunity Analysis and Industry Forecast, 2021-2022 & 2031: Affordable Access to Generic Finasteride Fuel Market Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 13, 2023
Health, Other Health, Clinical Trials, Research, Pharmaceutical, Science, Male, Finasteride, Laboratory, Prevalence, Hair loss, Sun Pharma, Medicine, BPH, Organon & Co., Market, Incidence, National library, Application, Porter's five forces analysis, Distribution, Aurobindo Pharma, Growth, Merck, Merck & Co., Benchmarking, Intas Pharmaceuticals, Organon, Video game, Generic drug, Retail, Marketing

The "Finasteride Market By Application, By Type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Finasteride Market By Application, By Type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
  • In addition, a rise in prevalence of benign prostatic hyperplasia (BPH) is expected to fuel the market growth.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the finasteride market analysis from 2021 to 2031 to identify the prevailing finasteride market opportunities.
  • The report includes the analysis of the regional as well as global finasteride market trends, key players, market segments, application areas, and market growth strategies.

HAIR LOSS AWARENESS MONTH 2023

Retrieved on: 
Thursday, July 27, 2023
Blood pressure, Hair, Radical, Dutasteride, University, Telogen effluvium, Hair loss, Oxygen, Physician, Overalls, Heredity, Ageing, BOCA, Woman, Research, Cell, Static pressure, Dicarboxylic acid, Pigment, Scalp, Regenerative medicine, FUE, Nitric oxide, Formula, Regeneration, Pattern hair loss, PRP, Patient, Plasma, Finasteride, Growth, Worldwide Angel, FDA, News, Memory, Skin, Peptide, Disease, TED, Medical device, Dentistry, Cosmetics, Dietary supplement

BOCA RATON, Fla., July 27, 2023 /PRNewswire/ -- While for many August marks the final stretch of summer frolicking and fun, the medical community utilizes the month as an opportunity to focus on hair loss and the scientific breakthroughs that will benefit millions of Americans suffering with the complex medical condition. The American Hair Loss Association estimates that at least 80 million men and women are currently suffering from the disease across the country. August officially marks Hair Loss Awareness Month (HLAM) and is advantageous for addressing advancements in treatments and technology. Internationally recognized, ABHRS-Certified Hair Restoration Surgeon Dr. Alan J. Bauman, and mastermind behind Biohacking Baldness, reveals the newest effective treatments and technology aimed at both preserving and restoring hair.

Key Points: 
  • August officially marks Hair Loss Awareness Month (HLAM) and is advantageous for addressing advancements in treatments and technology.
  • Hair Restoration Surgeon Dr. Alan J. Bauman reveals the newest effective treatments and technology for restoring hair.
  • Today's state-of-the-art hair transplant technology includes the no-linear-scar, minimally-invasive FUE hair transplant surgery as well as the No-Shave Long-Hair VIP|FUE™, a groundbreaking minimally-invasive hair transplant procedure.
  • It supports Hair Restoration Physicians and patients by comparing robust and weak hair growth areas and precisely tracks hair growth over time.

Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities

Retrieved on: 
Monday, July 17, 2023
Telehealth, Business development, Senior, Marketing, Wake (Dead Can Dance album), IQVIA, BPH, Biotechnology, Eye, Prescription, Bluewater, Pharmacy, Master service agreement, Acquisition, Patient, Tadalafil, Physician, Finasteride, Capital, Pain management, Growth, Cardiology, FDA, Letter, Urology, Pharmaceutical industry, Management, Sales, Health insurance

In recent months, Blue Water Biotech, Inc. (“Blue Water”) has evolved from a preclinical vaccine development company to a commercial stage pharmaceutical company after the purchase of several FDA approved assets spanning multiple treatment areas.

Key Points: 
  • In recent months, Blue Water Biotech, Inc. (“Blue Water”) has evolved from a preclinical vaccine development company to a commercial stage pharmaceutical company after the purchase of several FDA approved assets spanning multiple treatment areas.
  • While each product has unique considerations for launch and we have analyzed each closely, we have developed a core framework for commercial operations as we progress towards official launch.
  • To begin, the core for any successful commercial operation is a dedicated, experienced management team to steer operations and make strategic decisions that will benefit Blue Water in the long run.
  • To summarize, the last few months have certainly been an exciting time for Blue Water, filled with acquisitions, growth, and execution.

Half of Women Experience Hair Loss; Hers Unveils Innovative Line of Personalized Solutions

Retrieved on: 
Tuesday, June 13, 2023
Technology, Women, Fitness & Nutrition, Specialty, Internet, Health, Cosmetics, Consumer, Retail, Selenium, Zinc, Senior, Minoxidil, Hair loss, Coles, Biotin, Woman, Innovation, Multimedia, Research, Pharmacy, Hims & Hers Health, Vitamin, Spironolactone, Hers, Beauty, Dietary supplement, Finasteride, Homs, NYSE

Available now, the Hair Blends line provides access to formulations that are designed for women who may benefit from more personalized options to treat hair loss.

Key Points: 
  • Available now, the Hair Blends line provides access to formulations that are designed for women who may benefit from more personalized options to treat hair loss.
  • “We found that only one in four women experiencing hair loss talk to a doctor and so might not be aware of the doctor-trusted ingredients available to treat hair loss.
  • Hair Blends includes treatment options in a range of formats, from oral to topical, designed to provide women access to personalized solutions that should feel convenient while treating their hair loss.
  • Women seeking personalized solutions for hair loss can connect with a licensed medical provider at forhers.com, who will determine if treatment is right for them.

Veru Reports Fiscal 2023 Second Quarter Financial Results

Retrieved on: 
Thursday, May 11, 2023
Operating cost, Internet, Telephone, Oxygen, Survival, Incidence, Capsule, Patient, Finasteride, Eli Lilly and Company, GPO, SERD, Agreement, Telehealth, BPH, Drug discovery, Animal law, Enobosarm, Metastasis, Comorbidity, FC2, FDA, IND, Combination, Safety, EUA, High Risk, CDK, COVID-19, Metastatic breast cancer, AGS, Trust, Mortality, LPC, ORR, SARS-CoV-2, NDA, Quality of life, Pharmacy, Prostate, Sale, Trial of the century, Emergency Use Authorization, Tadalafil, Treatment, Breast cancer, Vaccine, Pharmaceutical industry, Birth control, Reinsurance, Cryptocurrency, Virus

ET

Key Points: 
  • ET
    MIAMI, FL, May 11, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced financial results for its fiscal 2023 second quarter and provided a business update.
  • On March 30, 2023, the Company met with the FDA to gain further regulatory clarity for the ongoing Phase 2b/3 clinical trial design and program.
  • Cash and cash equivalents were $23.5 million as of March 31, 2023 versus $80.2 million as of September 30, 2022.
  • To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call.

Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

Retrieved on: 
Thursday, April 20, 2023
Intellectual property, Business development, Pharmacy, Conference call, BPH, Quality of life, BWV, Prescription, Bluewater, Infection, Prostate, Burn, Testosterone (medication), Marketing, Outline, Acquisition, Patient, AbbVie, Risk, Finasteride, Sildenafil, Webcast, Knowledge, Growth, Erectile dysfunction, FDA, Conference, Pharmaceutical industry, IQVIA, Tadalafil

CINCINNATI, April 20, 2023 (GLOBE NEWSWIRE) --  Blue Water Vaccines Inc. (“BWV” or “Blue Water” or the “Company”), today announced the signing of an Asset Purchase Agreement (the “Agreement”) with Veru Inc. (“Veru”) for the purchase of ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia (“BPH”) that counteracts negative sexual side effects seen in men on alternative BPH therapies.

Key Points: 
  • Blue Water will also assume royalty and milestone obligations under a previous asset purchase agreement, including a royalty on all sales and sales milestone payments of up to $22.5 million.
  • Men with BPH suffer from challenges with urination flow, frequency, and urgency, and about 70% of men with BPH also experience sexual dysfunction.
  • “This purchase provides us an opportunity to advance Blue Water into the commercial space and to offset burn to provide key revenue supporting our vaccine candidate pipeline.
  • Through this transformative acquisition, Blue Water expands to become a broader pharmaceutical company and will rely on its experienced management and leadership to drive success.

Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones

Retrieved on: 
Thursday, April 20, 2023
SARS-CoV-2, BPH, Bluewater, Sale, Tadalafil, Finasteride, FC2, Pharmaceutical industry

MIAMI, FL, April 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related diseases, today announced the sale of its ENTADFI® (finasteride and tadalafil) capsules business for benign prostatic hyperplasia (BPH) to Blue Water Vaccines, Inc. (NASDAQ: BWV) for $20 million and up to an additional $80 million from sales milestones.

Key Points: 
  • MIAMI, FL, April 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related diseases, today announced the sale of its ENTADFI® (finasteride and tadalafil) capsules business for benign prostatic hyperplasia (BPH) to Blue Water Vaccines, Inc. (NASDAQ: BWV) for $20 million and up to an additional $80 million from sales milestones.
  • Under the terms of the agreement, Veru received $6 million at closing and Blue Water is obligated to pay the Company an additional $4 million in the Company’s fiscal year 2023, and an additional $10 million in installments in the Company’s fiscal year 2024.
  • In addition, Veru could receive up to an additional $80 million if certain ENTADFI sales milestones are achieved.
  • “The sale of ENTADFI and revenues from our FC2 business provide Veru with financial flexibility and resources to advance our important drug candidates, enobosarm for 2nd line AR+ ER+ HER2- metastatic breast cancer and sabizabulin for SARS-CoV-2 viral ARDS, that could yield Phase 3 clinical trial data in 2024,” said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru Inc.

Stud Rx Now Offering Men's Health Compounded Hair Loss and Hygiene Solutions

Retrieved on: 
Thursday, April 6, 2023
Overalls, Male, Hair, Pharmacist, Erectile dysfunction, Health, FDA, Minoxidil, Hair loss, Finasteride, Scalp, Cosmetics, Birth control

HOUSTON, April 6, 2023 /PRNewswire/ -- Today, Stud Rx is proud to announce the launch of a new line of men's health compounded hair loss and hygiene products.

Key Points: 
  • HOUSTON, April 6, 2023 /PRNewswire/ -- Today, Stud Rx is proud to announce the launch of a new line of men's health compounded hair loss and hygiene products.
  • This expansion into the men's telehealth health space provides solutions for hair loss, skincare, and erectile dysfunction treatments.
  • Meanwhile, minoxidil helps stimulate hair growth by increasing blood flow to hair follicles and causing resting follicles to grow hair again—and the result is often thicker hair.
  • With this new product launch Stud Rx hopes to revolutionize the way men receive care when it comes to their health needs.